ROYAL BANK OF CANADA - ENANTA PHARMACEUTICALS INC ownership

ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 155 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 2.37 and the average weighting 0.1%.

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of ENANTA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$41,000
-28.1%
3,716
+39.4%
0.00%
Q2 2023$57,000
-10.9%
2,665
+68.7%
0.00%
Q1 2023$64,000
-59.0%
1,580
-52.9%
0.00%
Q4 2022$156,000
+333.3%
3,357
+376.2%
0.00%
Q3 2022$36,000
+33.3%
705
+22.2%
0.00%
Q2 2022$27,000
-77.3%
577
-65.4%
0.00%
Q1 2022$119,000
-56.6%
1,668
-54.4%
0.00%
Q4 2021$274,000
+98.6%
3,656
+51.1%
0.00%
Q3 2021$138,000
+122.6%
2,420
+71.8%
0.00%
Q2 2021$62,000
+1450.0%
1,409
+1367.7%
0.00%
Q1 2021$4,000
-98.1%
96
-98.1%
0.00%
Q4 2020$212,000
-16.9%
5,024
-9.9%
0.00%
Q3 2020$255,000
+9.0%
5,576
+19.5%
0.00%
Q2 2020$234,000
-8.2%
4,668
-5.8%
0.00%
Q1 2020$255,000
+4150.0%
4,953
+5283.7%
0.00%
Q4 2019$6,000
-14.3%
92
-28.1%
0.00%
Q3 2019$7,000
-70.8%
128
-55.9%
0.00%
Q2 2019$24,000
-14.3%
2900.0%0.00%
Q1 2019$28,000
+33.3%
2900.0%0.00%
Q4 2018$21,000
-27.6%
290
-15.7%
0.00%
Q3 2018$29,000
-90.3%
344
-86.6%
0.00%
Q2 2018$298,000
-11.8%
2,574
-38.4%
0.00%
Q1 2018$338,000
+41.4%
4,180
+2.8%
0.00%
Q4 2017$239,000
-20.6%
4,065
-36.8%
0.00%
Q3 2017$301,000
+34.4%
6,433
+3.2%
0.00%
Q2 2017$224,000
-2.2%
6,231
-16.0%
0.00%
Q1 2017$229,000
+502.6%
7,420
+554.3%
0.00%
Q4 2016$38,000
+245.5%
1,134
+173.9%
0.00%
Q3 2016$11,000
-97.3%
414
-97.7%
0.00%
Q2 2016$402,000
-45.3%
18,245
-27.1%
0.00%
Q1 2016$735,000
+14.8%
25,019
+29.2%
0.00%
Q4 2015$640,000
-0.9%
19,360
+8.4%
0.00%
Q3 2015$646,000
-17.0%
17,864
+3.3%
0.00%
-100.0%
Q2 2015$778,000
+89.8%
17,301
+29.1%
0.00%
Q1 2015$410,000
+13.3%
13,406
+88.6%
0.00%
Q4 2014$362,000
+3520.0%
7,110
+2710.3%
0.00%
Q3 2014$10,000
-9.1%
253
+1.2%
0.00%
Q2 2014$11,000
-45.0%
250
-50.0%
0.00%
Q1 2014$20,000
+5.3%
500
-28.1%
0.00%
Q4 2013$19,0006950.00%
Other shareholders
ENANTA PHARMACEUTICALS INC shareholders Q2 2021
NameSharesValueWeighting ↓
Krensavage Asset Management, LLC 511,186$43,686,00011.23%
GREAT POINT PARTNERS LLC 210,400$17,981,0002.80%
ARMISTICE CAPITAL, LLC 456,000$38,970,0002.34%
Matarin Capital Management, LLC 210,208$17,964,376,0001.16%
Sapphire Star Partners LP 8,168$698,0000.70%
Granahan Investment Management 103,320$8,830,0000.48%
FARALLON CAPITAL MANAGEMENT LLC 867,500$74,137,0000.44%
361 CAPITAL LLC 19,040$1,627,0000.35%
ALGERT GLOBAL LLC 17,922$1,532,0000.33%
AlphaMark Advisors, LLC 9,310$796,0000.32%
View complete list of ENANTA PHARMACEUTICALS INC shareholders